Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFLX.L Regulatory News (FLX)

  • There is currently no data for FLX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

28 Mar 2019 07:00

RNS Number : 2249U
Falanx Group Limited
28 March 2019
 

Falanx Group Limited

 

("Falanx" or the "Company")

 

Appointment of Non-Executive Chairman

 

and

 

Update to Articles

 

Falanx Group Limited, the AIM listed global cybersecurity and intelligence provider, announces that Alexander Hambro is joining the Board as Non-Executive Chairman with immediate effect. Mike Read who has been acting CEO and Chairman since November 2017 will continue in the role of CEO.

 

Alex has been active in the investment sector both in the UK and the USA for some 30 years, during which time he has acted as a principal investor, manager and sponsor of private equity and venture capital management teams.

As well as his responsibilities at Falanx, Alex is a co-founder and Chairman of Judges Scientific plc, a group of scientific instrumentation companies. In addition to his two AIM company chair responsibilities, Alex is also Chairman of Crescent Capital Ltd and Bapco Closures Holdings Ltd and a Non-Executive Director of Octopus Apollo VCT plc, Hertsford Capital plc, Time Partners Holdings Ltd and Whitley Asset Management Ltd.

 

Alex is currently a principal at Welbeck Capital Partners, a specialist in the creation of secured convertible loan notes and other hybrid equity solutions to finance growth opportunities for small-cap AIM companies and which has supported Falanx during recent fundraisings.

 

Commenting Mike Read, CEO, said: "I am delighted that Alex has joined us. He brings considerable corporate finance and corporate governance experience to the business and his appointment as Non-Executive Chairman will allow me to focus on my role as CEO and drive forward our growth plans. Our changes to the Articles also underpin our strengthening corporate governance plans. We plan to appoint an additional experienced non-executive director in the coming few months."

 

Alex Hambro, Non-Executive Chairman, said: "I know the team at Falanx well and I am excited by the growth opportunities in the cyber security sector and Falanx's expansion plans within that framework. Mike and his team are well-positioned and experienced in making and integrating acquisitions and I am looking forward to supporting their growth."

 

Articles and Memorandum of Association (the "Articles")

The board of Falanx has passed certain resolutions aimed at updating its Articles (which are under British Virgin Islands law) and ensuring that, so far as is possible, these are closely aligned with those of typical UK AIM listed companies.

 

The key changes include introducing:

· pre-emption rights in order to protect shareholders against potential future dilution. Unless otherwise ratified by shareholders, the board will be restricted from issuing shares amounting to more than 12.5% of the fully diluted share capital for cash and up to a further 12.5% of the share fully diluted share capital to support acquisitions or other specified capital investments;

· provisions analogous to those contained in the UK Takeover Code. Whilst Falanx will remain outside the formal scope of the Takeover Code, the Board consider it to be in the best interests of shareholders for analogous provisions to be enshrined in the Articles;

· a requirement for the Company to hold an annual general meeting;

· disclosure provisions requiring shareholders to notify the Company of their interests in accordance with the provisions of Chapter 5 of the Disclosure and Transparency Rules as is typical for UK listed businesses; and

· a restriction on the board making any further changes to the Articles without shareholder approval.

The Articles also include a certain number of other tidying and technical changes and are published in full at www.falanx.com.

 

Enquiries:

 

Falanx Group Limited

Mike Read, Chairman and CEO

 

Via IFC

Stifel Nicolaus Europe Limited, Nomad and Joint Broker

Fred Walsh / Alex Price / Neil Shah / Luisa Baroni

+ 44 (0) 207 710 7600

Turner Pope International Limited, Joint Broker

James Pope / Ben Turner

+44 (0) 203 621 4120

 

IFC Advisory Ltd

Financial PR & IR

Graham Herring / Miles Nolan / Zach Cohen

+44 (0) 203 934 6630

 

About Falanx

Falanx Group Limited, is a global intelligence and cyber defence provider working with blue chip and government clients. For more information: http://www.falanx.com/

 

Regulatory disclosures

 

In accordance with Schedule 2(g) of the AIM Rules, Hon Alexander Hambro (aged 57) holds or has held in the past 5 years the following directorships and partnerships:

 

Current

Past five years

Bapco Closures Holdings Limited

Aldersgate House Ltd

Bapco Closures Research Limited

BACIT (UK) Limited

Crescent Capital II GP Limited

Benchmark Holdings plc

Crescent Capital III GP Limited

Gresham House Renewable Energy (formerly Hazel Renewable Energy VCT2 plc)

Crescent Capital NI Limited

Hazel Targa VCT plc

First Magazine Limited

Izon Science Ltd

Halkin Development Limited

Targa Fund Limited

Hertsford Capital plc

Welbeck Investment Partners Member Ltd

HF Partnership LLP

Welbeck Investment Partnership LLP

Octopus Eclipse VCT4 PLC

Judges Scientific plc

Octopus Eclipse VCT Plc (in voluntary liquidation)

Octopus Apollo VCT plc

Time Partners Holdings Ltd

Welbeck Capital Partners LLP

Welbeck Ventures Ltd

Whitley Asset Management Limited

 

Alexander Hambro is interested in 250,000 shares in Falanx Group Limited representing 0.06% of the current issued share capital.

 

Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUGCWUPBGAM
Date   Source Headline
9th Dec 20222:42 pmRNSHolding(s) in Company
8th Dec 20224:29 pmRNSResult of AGM
8th Dec 20227:00 amRNSInterim Results
24th Nov 20225:17 pmRNSHolding(s) in Company
15th Nov 20225:56 pmRNSNotice of AGM
18th Oct 20227:00 amRNSDirectorate Change
29th Sep 20227:00 amRNSFinal Results
20th Sep 20227:00 amRNSHolding(s) in Company
5th Sep 20224:53 pmRNSHolding(s) in Company
4th Aug 20222:06 pmRNSSecond Price Monitoring Extn
4th Aug 20222:00 pmRNSPrice Monitoring Extension
4th Aug 202211:05 amRNSSecond Price Monitoring Extn
4th Aug 202211:00 amRNSPrice Monitoring Extension
4th Aug 20227:00 amRNSTrading Update
9th May 20227:00 amRNSPartnership to Provide M-EDR to UK Customers
8th Apr 20224:06 pmRNSHolding(s) in Company
6th Apr 202211:59 amRNSHolding(s) in Company
1st Apr 20227:00 amRNSChange of Adviser
30th Mar 20222:44 pmRNSDirector/PDMR Shareholding
23rd Mar 202212:59 pmRNSDirector/PDMR Shareholding
10th Feb 202211:11 amRNSDirector/PDMR Shareholding
24th Jan 20227:00 amRNSDirector/PDMR Shareholding
19th Jan 20225:20 pmRNSHolding(s) in Company
19th Jan 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 202111:14 amRNSResult of AGM
7th Dec 20217:00 amRNSInterim Results
16th Nov 20212:10 pmRNSNotice of AGM
29th Oct 20211:57 pmRNSExercise of Options, TVR and PDMR dealing
27th Oct 20219:03 amRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSDirector/PDMR Shareholding
25th Oct 20213:25 pmRNSExercise of Options and TVR
13th Oct 202111:06 amRNSSecond Price Monitoring Extn
13th Oct 202111:00 amRNSPrice Monitoring Extension
13th Oct 20217:00 amRNSTrading update and BOOST&Co loan facility update
6th Oct 20214:41 pmRNSSecond Price Monitoring Extn
6th Oct 20214:35 pmRNSPrice Monitoring Extension
6th Oct 20212:43 pmRNSSale of Assynt for £4.6 million
4th Oct 20217:00 amRNSFalanx Launch Mass Market Security Assessment Tool
29th Sep 20217:00 amRNSAnnual results for the year ended 31 March 2021
18th Aug 20217:01 amRNSGrant of share options
18th Aug 20217:00 amRNSTrading Update & New Loan Facility
9th Jul 20219:07 amRNSHolding(s) in Company
29th Apr 20217:00 amRNSCancellation of unapproved Share Options
1st Apr 20217:00 amRNSIssue of Equity and TVR
26th Feb 20213:31 pmRNSResult of GM
10th Feb 20212:03 pmRNSPublication of Circular & Notice of GM
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
5th Feb 20217:00 amRNSContract Wins and Covid Business Interruption Loan
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.